AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 20.02 |
Market Cap | 2.19B |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | -2.61 |
PE Ratio (ttm) | -13.25 |
Forward PE | n/a |
Analyst | Buy |
Ask | 54.99 |
Volume | 587,480 |
Avg. Volume (20D) | 762,329 |
Open | 34.99 |
Previous Close | 34.77 |
Day's Range | 33.28 - 35.00 |
52-Week Range | 14.20 - 51.61 |
Beta | undefined |
About VERA
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy. It is also developing MAU868, a monoclonal antibody for the treatment of ...
Analyst Forecast
According to 8 analyst ratings, the average rating for VERA stock is "Buy." The 12-month stock price forecast is $66, which is an increase of 90.81% from the latest price.